GENB · Generate Biomedicines, Inc. · Analyst Estimates
$13.06
+0.49 (+3.90%)
At close · Nov 6
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern. Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company’s current capital resources, which consists of its cash, cash equivalents and marketable securities on hand at June 30, 2026, it expects to have sufficient cash to fund our current operating plan into the first half of 2028.”View the 10-Q filed Aug 6, 2026
Market Cap
$1.68B
Shares
128.35M
Volume · Nov 6
632.2K
Avg daily vol (3M)
1.2M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Analyst Estimates
Compare analyst forecasts for Generate Biomedicines, Inc. across metrics and forecast periods.
Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.
Compiled consensus
These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.
Captured 2026-10-14 19:23 UTC · Publication dates shown per estimate · 8 metric / period groups
FY ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-2.50
|
-2.30
|
-2.14
|
4
|
-2.30
|
-2.30
|
-2.35
|
-2.24
|
0
|
2
|
0
|
2
|
|
Revenue
USD
Publication date not stated |
23.50M
|
29.68M
|
38.50M
|
6
|
— | — | — | — | — | — | — | — |
FY ending 2027-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-2.72
|
-2.28
|
-1.53
|
4
|
-2.28
|
-2.28
|
-2.28
|
-2.07
|
2
|
2
|
0
|
0
|
|
Revenue
USD
Publication date not stated |
0.00
|
23.83M
|
40.00M
|
6
|
— | — | — | — | — | — | — | — |
Q ending 2026-09-30
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.67
|
-0.55
|
-0.44
|
4
|
-0.55
|
-0.55
|
-0.58
|
-0.54
|
0
|
2
|
0
|
1
|
|
Revenue
USD
Publication date not stated |
5.00M
|
7.75M
|
10.00M
|
5
|
— | — | — | — | — | — | — | — |
Q ending 2026-12-31
| Metric | Low | Average | High | Analyst count | Average, 7 days ago | Average, 30 days ago | Average, 60 days ago | Average, 90 days ago | Estimates lowered, last 7 days | Estimates lowered, last 30 days | Estimates raised, last 7 days | Estimates raised, last 30 days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
EPS
USD
Publication date not stated |
-0.63
|
-0.57
|
-0.44
|
4
|
-0.57
|
-0.57
|
-0.61
|
-0.55
|
0
|
2
|
0
|
1
|
|
Revenue
USD
Publication date not stated |
3.00M
|
7.65M
|
15.00M
|
5
|
— | — | — | — | — | — | — | — |
Key facts
CIK
2100782
CUSIP
370920100
13F (30d)
35 filings
35 filers
Visit website
Investor relations